Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Operating Leases for 6 consecutive years, with $415.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 8.75% year-over-year to $415.3 million, compared with a TTM value of $415.3 million through Dec 2025, down 8.75%, and an annual FY2025 reading of $415.3 million, down 8.75% over the prior year.
  • Operating Leases was $415.3 million for Q4 2025 at Neurocrine Biosciences, down from $479.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $489.8 million in Q2 2025 and bottomed at $90.4 million in Q1 2023.
  • Average Operating Leases over 4 years is $263.1 million, with a median of $252.9 million recorded in 2024.
  • The sharpest move saw Operating Leases surged 179.76% in 2024, then fell 8.75% in 2025.
  • Year by year, Operating Leases stood at $106.4 million in 2021, then skyrocketed by 78.38% to $189.8 million in 2023, then surged by 139.78% to $455.1 million in 2024, then fell by 8.75% to $415.3 million in 2025.
  • Business Quant data shows Operating Leases for NBIX at $415.3 million in Q4 2025, $479.7 million in Q3 2025, and $489.8 million in Q2 2025.